Brian Leyland-Jones, MD, PhD, director of the Emory Winship Cancer Institute, and Fadlo Khuri, MD, section head of hematology and oncology at Emory Winship, announced the appointment of Suresh Ramalingam, MD, as director of the translational thoracic malignancies program, and acting assistant professor of hematology and oncology, Emory University School of Medicine.
Dr. Ramalingam comes to Emory from the University of Pittsburgh School of Medicine. He specializes in lung cancer, esophageal cancer and other thoracic cancers and is actively involved in the scientific development of novel anti-cancer treatment agents.
"We are delighted to announce Dr. Ramalingam's appointment to the faculty here at Winship," says Dr. Leyland-Jones. "Dr. Ramalingam brings an exceptional background in patient care and research to Emory Winship. His dedication to advancing the body of knowledge in cancer research and his devotion to excellent patient care represents the very best in translational cancer research and treatment. Dr. Ramalingam will contribute immediately to our drive toward NCI Comprehensive Cancer Center designation."
Dr. Ramalingam serves as the principal investigator on several early phase clinical trials in lung cancers, many of which are sponsored by the NCI. He is widely published in peer-reviewed scientific journals and serves as a reviewer for a number of medical journals. Dr. Ramalingam is a member of the Thoracic Core Committee of the Eastern Cooperative Oncology Group and serves on the editorial board of the journal Clinical Lung Cancer.
"Dr. Ramalingam is a critical addition to our faculty," says Dr. Khuri. "His growing national presence as a thought leader in the treatment of thoracic malignancies, and his outstanding patient care skills and substantial experience in clinical trial development will all have a tremendous impact on our ability to bring new and innovative lung cancer treatment to patients throughout Georgia.
"We are fortunate to have recruited him, and he will prove a major asset, not just to Emory and to all of our colleagues in the community, but most importantly, to the many patients afflicted with the diseases he has dedicated his career to treating," says Dr. Khuri.
Dr. Ramalingam is a recipient of the prestigious "Clinical Research Career Development Award," which is presented by the American Society of Clinical Oncology. He has been selected as one of "The Best Doctors in America" and has received numerous awards of excellence such as The University of Pittsburgh Leadership Award for Excellence in Clinical Trials Program Development.
"Emory Winship Cancer Institute is strongly positioned to move to the next level as a national leader in top quality cancer care and research," says Dr. Ramalingam. "I am excited to join Emory at this critical juncture. Working closely with the team of highly accomplished researchers at Emory, we will provide top-notch cancer care for patients and offer innovative, cutting-edge clinical trials for the treatment of lung cancer."
About the Emory Winship Cancer Institute:
As a leader in patient-centered cancer care and research, Emory University's Winship Cancer Institute serves as the coordinating center for a vast array of resources in medical, surgical, radiation oncology, diagnostic imaging, and the subspecialties of cancer care throughout Emory University from blood and bone marrow stem cell transplants to internationally recognized breast reconstruction.
Winship's 280,000-square-foot building houses research and clinical cancer services and is designed as a pavilion in which patients, doctors, nurses and researchers are all brought together under one roof. It also serves as a "discovery accelerator" where care of cancer patients is advanced through groundbreaking discoveries in genomics and molecular medicine.